WO2023203549 - METHODS OF ACHIEVING SAFE AND SUSTAINED CONTROL OF IL-17-DEPENDENT CONDITIONS IN SUBJECTS RESPONSIVE TO TREATMENT WITH AN ANTI-IL 17A/F NANOBODY
National phase entry:
Publication Number
WO/2023/203549
Publication Date
26.10.2023
International Application No.
PCT/IB2023/054122
International Filing Date
21.04.2023
Title **
[English]
METHODS OF ACHIEVING SAFE AND SUSTAINED CONTROL OF IL-17-DEPENDENT CONDITIONS IN SUBJECTS RESPONSIVE TO TREATMENT WITH AN ANTI-IL 17A/F NANOBODY
[French]
PROCÉDÉS D'OBTENTION D'UNE COMMANDE SÛRE ET PROLONGÉE D'ÉTATS DÉPENDANTS DE L'IL-17 CHEZ DES SUJETS SENSIBLES À UN TRAITEMENT AVEC UN NANOCORPS ANTI-IL17A/F
Applicants **
MOONLAKE IMMUNOTHERAPEUTICS AG
Inventors
REICH, Kristian
Priority Data
63/333,920
22.04.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2890 | |
| EPO | Filing, Examination, Granting | 21544 | |
| Japan | Filing, Examination, Granting | 2962 | |
| South Korea | Filing, Examination, Granting | 3576 | |
| USA | Filing, Examination, Granting | 9340 |
Total:
40,312
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are methods of treating psoriasis and other IL-17-dependent conditions with an anti-interleukin 17A/F nanobody for approximately 24 weeks, followed by withdrawal of treatment in responding patients with the anti-interleukin 17A/F nanobody for a period of at least 4-20 weeks. Disease modification may be achieved by no later than week 24 with the anti- interleukin 17A/F nanobody such that responders may demonstrate sustained normalization of peripheral and/or cutaneous biomarkers such as IL-17A, IL-17F, and/or IL-22. Treatment methods as contemplated herein which have been paused may be re-started based on the subject's condition. Treatment beyond 24 weeks also achieves unexpectedly high efficacy in responders who have not quite reached full skin clearance in the initial treatment period.[French]
L'invention concerne des procédés de traitement du psoriasis et d'autres affections dépendantes de l'IL-17 avec un nanocorps anti-interleukine 17A/F pendant environ 24 semaines, suivis de l'arrêt du traitement chez des patients répondant au nanocorps anti-interleukine 17A/F pendant une période d'au moins 4 à 20 semaines. Une modification de maladie peut être obtenue par pas plus tard que la semaine 24 avec le nanocorps anti-interleukine 17A/F de telle sorte que les répondeurs peuvent démontrer une normalisation prolongée de biomarqueurs périphériques et/ou cutanés tels que l'IL-17A, l'IL-17 F, et/ou l'IL-22. Les procédés de traitement selon la présente invention qui ont été mis en pause peuvent être redémarrés sur la base de l'état du sujet. Le traitement au-delà de 24 semaines atteint également une efficacité étonnamment élevée chez des répondeurs qui n'ont pas atteint de clairance de peau complète dans la période de traitement initiale.